1-异丙基吡唑-5-硼酸频哪醇酯 | 1282518-60-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸酯
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 1-异丙基吡唑-5-硼酸频哪醇酯
• 中文别名: 1-异丙基-5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1H-吡唑
• 英文名称: 1-isopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• 英文别名: 1-propan-2-yl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole
• CAS: 1282518-60-8
• 化学式: C₁₂H₂₁BN₂O₂
• 分子量: 236.122
• InChiKey: ZKZJXVGTTZXHGX-UHFFFAOYSA-N

物化性质

• 沸点：
  327.3±15.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.76
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Isopropyl-1H-pyrazole-5-boronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Isopropyl-1H-pyrazole-5-boronic acid, pinacol ester
CAS number: 1282518-60-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H21BN2O2
Molecular weight: 236.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-异丙基吡唑-5-硼酸频哪醇酯 在 盐酸 、 四(三苯基膦)钯 、 氯化亚砜 、 sodium carbonate 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 沃塞洛托
  参考文献：
  名称：

  一个实用的体素合成器

  摘要：

  由市售化学品吡唑、2-氯烟酸和二甲氧基苯开发了一种改进的实用合成体素(1) 。关键中间体 (2-[1-isopropyl-1 H -pyrazol-5-yl]pyridin-3-yl) 甲醇(8)经 4 个步骤（包括还原和交叉偶联缩合）以 45% 的收率制备。2,6-二羟基苯甲醛 ( 24 ) 经 2 个步骤以 68% 的收率制备。最后，从这个收敛的合成路线通过 8 个步骤获得1 ，总产率为 25%，纯度为 99.2%，20 克规模。

  DOI：

  10.1002/jhet.4535
• 作为产物：
  描述：

  异丙醇频哪醇硼酸酯 、 1-异丙基吡唑 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.0h， 以65%的产率得到1-异丙基吡唑-5-硼酸频哪醇酯
  参考文献：
  名称：

  一个实用的体素合成器

  摘要：

  由市售化学品吡唑、2-氯烟酸和二甲氧基苯开发了一种改进的实用合成体素(1) 。关键中间体 (2-[1-isopropyl-1 H -pyrazol-5-yl]pyridin-3-yl) 甲醇(8)经 4 个步骤（包括还原和交叉偶联缩合）以 45% 的收率制备。2,6-二羟基苯甲醛 ( 24 ) 经 2 个步骤以 68% 的收率制备。最后，从这个收敛的合成路线通过 8 个步骤获得1 ，总产率为 25%，纯度为 99.2%，20 克规模。

  DOI：

  10.1002/jhet.4535

文献信息

• 1:1 ADDUCTS OF SICKLE HEMOGLOBIN
  申请人：Global Blood Therapeutics, Inc.

  公开号：US20150209443A1

  公开（公告）日：2015-07-30

  Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

  本文提供了镰刀形血红蛋白（HbS）与一种具有如下定义的化合物（I）的1:1加合物，适用作为HbS的调节剂，并提供了在治疗由血红蛋白介导的疾病以及那些会受益于组织和/或细胞氧合的疾病中使用它们的方法。
• [EN] 1:1 ADDUCTS OF SICKLE HEMOGLOBIN<br/>[FR] PRODUITS D'ADDITION 1:1 D'HÉMOGLOBINE S
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2015116061A1

  公开（公告）日：2015-08-06

  Provide herein are 1:1 adducts of sickle hemoglobin (HbS) and a compound of formula (I), as defined herein, suitable as modulators of HbS, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

  本文提供了镰刀血红蛋白（HbS）与本文定义的化合物（I）的1:1加合物，适用作为HbS的调节剂，并提供了在治疗由血红蛋白介导的疾病以及需要组织和/或细胞氧合的疾病中使用它们的方法。
• [EN] PROCESS FOR SYNTHESIZING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)-PYRIDIN-3-YL)METHOXY)BENZALDEHYDE<br/>[FR] PROCÉDÉ DE SYNTHÈSE DE 2-HYDROXY-6-((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)MÉTHOXY)BENZALDÉHYDE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2017197083A1

  公开（公告）日：2017-11-16

  Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H- pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.

  本文披露了合成2-羟基-6-((2-(1-异丙基-1H-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛（以下简称为化合物(I)）及用于此类过程的中间体的方法。化合物(I)与血红蛋白结合，增加其氧亲和力，因此可用于治疗镰状细胞病等疾病。
• BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE
  申请人：Heffron Timothy

  公开号：US20120245144A1

  公开（公告）日：2012-09-27

  Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  本句翻译为中文是：苯并恶唑啉I型化合物，包括立体异构体、几何异构体、互变异构体、代谢物以及药学上可接受的盐，对于抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病如炎症、免疫疾病和癌症是有用的。公开了使用I型化合物公式进行体外、原位和体内诊断、预防或治疗哺乳动物细胞中此类疾病或相关病理状况的方法。
• [EN] ALDEHYDE COMPOUNDS FOR TREATING PULMONARY FIBROSIS, HYPOXIA, AND CONNECTIVE TISSUE AND AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS ALDÉHYDE POUR LE TRAITEMENT DE LA FIBROSE PULMONAIRE, DE L'HYPOXIE, ET DE MALADIES AUTO-IMMUNES ET DES TISSUS CONJONCTIFS
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2016160755A1

  公开（公告）日：2016-10-06

  This disclosure relates to use of certain aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease such as scleroderma, lupus, arthritis and related conditions in a mammal.

  这项披露涉及在哺乳动物中使用某些醛类化合物治疗肺纤维化、缺氧以及结缔组织和自身免疫疾病，如硬皮病、红斑狼疮、关节炎和相关疾病。